DUBLIN, Ohio, Aug. 2, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) and Hellman & Friedman (H&F) announced today the completion of the previously announced sale of Cardinal Health's Cordis ...

Cardinal Health, Inc. CAH recently inked a deal to divest its Cordis business to Hellman & Friedman (H&F) for an amount of around $1 billion. Notably, the transaction is anticipated to be ...

DUBLIN, Ohio, March 12, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today announced that it has signed a definitive agreement to sell its Cordis business to Hellman & Friedman (H&F) for ...

Cardinal Health expects a pre-tax loss of up to $120 million in the third quarter of its fiscal year 2021 after the deal closes. Johnson & Johnson JNJ.N sold the Cordis unit to Cardinal Health for ...

Cardinal Health Inc. said it agreed to sell its Cordis unit to private-equity firm Hellman & Friedman for about $1 billion, including the assumption of certain liabilities and Cardinal’s ...

Cordis makes cardiology and endovascular devices. Johnson & Johnson sold the business to Cardinal Health in 2015 for about $2 billion.. The sale of the business to Hellman & Friedman is expected ...

Cordis' international presence includes operations in China, Japan, Germany, Italy, France, the United Kingdom, and Brazil, among others. In recognition of its strong brand equity, Cordis products ...

Cardinal Health Inc (NYSE: CAH) has agreed to sell its Cordis business to Hellman & Friedman, a private equity firm, for approximately $1 billion. The deal value includes the buyer's assumption of ...

/PRNewswire/ -- Cardinal Health today announced that it has completed the acquisition of Johnson & Johnson's Cordis business, a global leader in cardiology and ...